← FDA DRUG APPROVALS

FDA ANDA · ANDA090260

LORAZEPAM

Sponsor: PHARM ASSOC

APPLICATION
ANDA090260
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-15
LATEST ACTION
2010-11-23
ROUTE
ORAL
DOSAGE FORM
CONCENTRATE
MARKETING STATUS
Prescription

Products

LORAZEPAMPrescription
LORAZEPAM 2MG/ML · CONCENTRATE · ORAL

Approval history

2010-11-23Labeling · Supplement 1AP
2010-06-15OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →